Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20 2023 - 8:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-classi therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced that management will participate in a fireside chat at
the 35th Annual Piper Sandler Healthcare Conference on Tuesday,
November 28, 2023 at 3:00 p.m. ET.
To access the live or archived recording of the discussion,
please visit the investor section of the Tempest website at
https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company has a diverse portfolio
of novel programs ranging from early research to investigation in a
randomized global study in first-line cancer patients. The
company’s two clinical programs, TPST-1120 and TPST-1495, target
PPARα and EP2/EP4, respectively, and are advancing through trials
designed to study the agents as monotherapies and in combination
with approved agents. Tempest is also developing an orally
available inhibitor of TREX1, a target that controls activation of
the cGAS/STING pathway. Tempest is headquartered in Brisbane,
California. More information about Tempest can be found on the
company’s website at www.tempesttx.com.
Investor & Media Contacts
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisors areynolds@wheelhouselsa.com
__________________________________i If approved by the
FDA
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Apr 2024 to May 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From May 2023 to May 2024